Mirum Pharmaceuticals SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 26, 2026, 4:47 p.m. ETView on SEC.gov
Other events
AI summary, unreviewedMirum Pharmaceuticals Reports Positive Cohort 2 PROGRESS Results for ATEBRIOZ in Pediatric FOP Patients Aged 6 to <12 Years
4Oct. 19, 2026, 4:10 p.m. ETView on SEC.gov
4Oct. 14, 2026, 4:06 p.m. ETView on SEC.gov
8-KOct. 13, 2026, 8:09 a.m. ETView on SEC.gov
Other events
AI summary, unreviewedMirum Pharmaceuticals Phase 3 EXPAND Study of LIVMARLI Meets Primary Endpoint in Ultra-Rare Cholestatic Liver Diseases, Plans sNDA in 1H 2027
4Oct. 6, 2026, 8:38 p.m. ETView on SEC.gov
8-KSept. 28, 2026, 8:02 a.m. ETView on SEC.gov
Other events
4Sept. 15, 2026, 4:10 p.m. ETView on SEC.gov
8-KSept. 8, 2026, 8:34 a.m. ETView on SEC.gov
Departure/appointment of directors or officers
4Sept. 3, 2026, 6:54 p.m. ETView on SEC.gov
4Sept. 3, 2026, 6:52 p.m. ETView on SEC.gov
4Aug. 19, 2026, 6:19 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 13, 2026, 12:47 p.m. ETView on SEC.gov
4Aug. 12, 2026, 5:14 p.m. ETView on SEC.gov
4Aug. 11, 2026, 5:41 p.m. ETView on SEC.gov
SCHEDULE 13GAug. 6, 2026, 10:33 a.m. ETView on SEC.gov
4Aug. 5, 2026, 4:26 p.m. ETView on SEC.gov
10-QAug. 5, 2026, 4:06 p.m. ETView on SEC.gov
8-KAug. 5, 2026, 4:02 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits